BioStock: New positive results for Curasight in brain cancer

Curasight’s recently announced preclinical results showed uTREAT’s potential in inhibiting glioblastoma growth. Adding to this milestone, the company has now also announced encouraging phase II results for uTRACE, demonstrating its prognostic value for survival outcomes in primary glioblastoma patients. BioStock contacted CEO Ulrich Krasilnikoff to learn more about what this means for the company.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/06/new-positive-results-for-curasight-in-brain-cancer/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se